Sarepta Therapeutics (SRPT) Operating Leases (2019 - 2026)

Sarepta Therapeutics' Operating Leases history runs 8 years deep, the most recent figure standing at $198.5 million for Q1 2026.

• In Q1 2026, Operating Leases fell 3.39% year-over-year to $198.5 million; the TTM figure through Mar 2026 stood at $198.5 million (down 3.39% YoY), while the FY2025 annual figure was $199.4 million, up 3.59% from the prior year.
• Operating Leases was $198.5 million for Q1 2026 at Sarepta Therapeutics, roughly flat from $199.4 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $215.0 million in Q3 2025 to a low of $35.2 million in Q3 2022.
• Historically, Operating Leases has averaged $135.8 million across 5 years, with a median of $141.0 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Operating Leases slumped 44.46% in 2022, then surged 282.5% in 2023.
• A 5-year view of Operating Leases shows it stood at $57.6 million in 2022, then jumped by 144.82% to $141.0 million in 2023, then jumped by 36.54% to $192.5 million in 2024, then gained by 3.59% to $199.4 million in 2025, then decreased by 0.44% to $198.5 million in 2026.
• The last three Operating Leases figures came in at $198.5 million (Q1 2026), $199.4 million (Q4 2025), and $215.0 million (Q3 2025), per Business Quant data.